Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
Small structural changes in peptides presented by major histocompatibility complex (MHC) molecules often result in large changes in immunogenicity, supporting the notion that T cell receptors are exquisitely sensitive to antigen structure. Yet there are striking examples of TCR recognition of structurally dissimilar ligands. The resulting unpredictability of how T cells will respond to different or modified antigens impacts both our understanding of the physical bases for TCR specificity as well as efforts to engineer peptides for immunomodulation. In cancer immunotherapy, epitopes and variants derived from the MART-1/Melan-A protein are widely used as clinical vaccines. Two overlapping epitopes spanning amino acid residues 26 through 35 are of particular interest: numerous clinical studies have been performed using variants of the MART-1 26-35 decamer, although only the 27-35 nonamer has been found on the surface of targeted melanoma cells. Here, we show that the 26-35 and 27-35 peptides adopt strikingly different conformations when bound to HLA-A2. Nevertheless, clonally distinct MART-1(26/27-35)-reactive T cells show broad cross-reactivity towards these ligands. Simultaneously, however, many of the cross-reactive T cells remain unable to recognize anchor-modified variants with very subtle structural differences. These dichotomous observations challenge our thinking about how structural information on unligated peptide/MHC complexes should be best used when addressing questions of TCR specificity. Our findings also indicate that caution is warranted in the design of immunotherapeutics based on the MART-1 26/27-35 epitopes, as neither cross-reactivity nor selectivity is predictable based on the analysis of the structures alone.
Borbulevych
Oleg Y
OY
Department of Chemistry and Biochemistry, 251 Nieuwland Science Hall, University of Notre Dame, Notre Dame, IN 46556, USA.
Insaidoo
Francis K
FK
Baxter
Tiffany K
TK
Powell
Daniel J
DJ
Johnson
Laura A
LA
Restifo
Nicholas P
NP
Baker
Brian M
BM
D000951:Antigens, Neoplasm / Q000737:chemistry*; D019496:Cancer Vaccines / Q000276:immunology; D018360:Crystallography, X-Ray; D000939:Epitopes / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D015789:HLA-A2 Antigen / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D010455:Peptides / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D011487:Protein Conformation; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes; D015789:HLA-A2 Antigen; C105787:MART-1-Melan-A(27-35) epitope; D009363:Neoplasm Proteins; D010455:Peptides; D011948:Receptors, Antigen, T-Cell
J Struct Biol. 1999 Apr-May;125(2-3):156-65
10222271
J Immunol. 1999 May 1;162(9):5389-97
10228016
Int J Cancer. 1999 Aug 27;82(5):669-77
10417764
Immunity. 1999 Jul;11(1):45-56
10435578
J Exp Med. 1999 Sep 6;190(5):705-15
10477554
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11446-51
10500196
Nat Struct Biol. 1999 Dec;6(12):1118-21
10581552
J Biol Chem. 1999 Dec 24;274(52):37259-64
10601290
J Immunol. 2000 Jun 15;164(12):6398-405
10843695
Nat Immunol. 2000 Oct;1(4):291-7
11017099
J Immunol. 2001 Mar 1;166(5):3345-54
11207290
Cancer Res. 2001 Mar 1;61(5):2047-54
11280765
J Biol Chem. 2001 Jun 15;276(24):21443-9
11287414
J Immunol. 2001 Sep 15;167(6):3276-84
11544315
J Exp Med. 2002 Feb 18;195(4):485-94
11854361
Immunity. 2002 Mar;16(3):345-54
11911820
J Exp Med. 2002 Jul 15;196(2):207-16
12119345
Nature. 2002 Aug 1;418(6897):552-6
12152083
Immunol Rev. 2002 Oct;188:81-96
12445283
Nat Immunol. 2003 Mar;4(3):241-7
12563259
J Biol Chem. 2003 May 16;278(20):18581-7
12604595
J Mol Biol. 2003 Mar 28;327(3):719-34
12634064
Cancer Res. 2003 Apr 1;63(7):1560-7
12670905
J Exp Med. 2004 Jan 19;199(2):271-81
14734527
J Biol Chem. 2004 Jul 2;279(27):28197-201
15084610
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
15299926
J Immunol. 2004 Nov 1;173(9):5610-6
15494511
J Exp Med. 2004 Dec 6;200(11):1445-54
15557346
J Exp Med. 2004 Dec 6;200(11):1455-66
15583017
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3429-33
1565634
J Clin Invest. 2005 Mar;115(3):739-46
15696196
J Immunol. 2005 Apr 15;174(8):4812-20
15814707
J Immunol. 2005 Oct 1;175(7):4797-805
16177129
Structure. 2006 Apr;14(4):683-93
16615910
Science. 2006 Oct 6;314(5796):126-9
16946036
J Mol Biol. 2006 Oct 13;363(1):228-43
16962135
J Immunol. 2006 Nov 1;177(9):6548-59
17056587
Nat Immunol. 2007 Mar;8(3):268-76
17259989
EMBO J. 2007 Apr 4;26(7):1972-83
17363906
Methods Enzymol. 1997;276:307-26
27754618
J Exp Med. 1994 Jul 1;180(1):347-52
7516411
J Immunol. 1995 Mar 1;154(5):2257-65
7868898
Science. 1994 Jul 15;265(5170):398-402
8023162
J Mol Biol. 1993 Jun 20;231(4):1049-67
8515464
J Immunol. 1996 Sep 15;157(6):2539-48
8805655
Science. 1996 Oct 11;274(5285):209-19
8824178
Nature. 1996 Nov 14;384(6605):134-41
8906788
J Immunol. 1997 Sep 1;159(5):2366-74
9278327
J Immunol. 1998 Feb 15;160(4):1750-8
9469433
Science. 1998 Feb 20;279(5354):1166-72
9469799
Nat Med. 1998 Mar;4(3):321-7
9500606
J Immunol. 1998 Apr 15;160(8):3631-6
9558061
Immunity. 1998 Apr;8(4):403-11
9586631
Bioinformatics. 1998;14(6):523-8
9694991
J Immunol. 1998 Dec 15;161(12):6956-62
9862730
J Exp Med. 1999 Jan 18;189(2):359-70
9892618
Cancer Res. 1999 Jan 15;59(2):301-6
9927036